On September 24, 2026 SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, reported new preclinical data evaluating unmodified human γδ T cells in glioblastoma (GBM) — the Company’s unmodified γδ T cell therapy platform (the "GDT platform"). The findings are being presented as poster P-2017 at the 85th Annual Meeting of the Japanese Cancer Association, held from September 24–26, 2026. The research was conducted in collaboration with investigators at Taipei Medical University (TMU), JY BioMed, and HeXun Biosciences.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key Data Presented
Targeting Resistant Cells: In advanced laboratory models, γδ T cells showed preferential cytotoxicity toward O6-methylguanine-DNA methyltransferase (MGMT)-positive GBM cells, which are typically resistant to standard chemotherapy.
Rapid Tumor Elimination: Real-time analysis across three distinct GBM cell lines (U87MG, T98G, and LN229) showed a dose-dependent drop in tumor cells upon the addition of γδ T cells.
Superior Efficacy: The γδ T cells exhibited higher cancer-killing activity than conventional αβ T cells in direct in vitro comparisons.
In Vivo Survival: Contextual data confirmed that the therapy reduced tumor size and prolonged survival in an intracranial GBM model, without obvious tolerability issues or macroscopic adverse findings.
Overcoming Standard Chemotherapy Limits
Glioblastoma is traditionally treated with surgery, radiotherapy, and the chemotherapy drug temozolomide. However, tumors reliably return. A key driver of this recurrence is the MGMT repair enzyme: cancer cells expressing this enzyme can reverse the DNA damage caused by chemotherapy, allowing them to survive treatment.
The new data show that SL Science’s γδ T cells directly address this chemo-resistant population. Because γδ T cells recognize general stress signals on cancer cells rather than relying on a single antigen, their cancer-killing ability is not hindered by the tumor’s DNA-repair mechanisms. In short, the cells are active against the exact fraction of the tumor that standard chemotherapy struggles to eliminate.
A Clear Development Pathway
This presentation marks the third recent milestone in a defined development sequence for the Company. It follows a July presentation in Melbourne demonstrating the therapy’s ability to control tumor growth in vivo, and an August peer-reviewed publication outlining the clinical development requirements for this modality. The current data helps answer a crucial third question: identifying which patients and tumor types are suited for this approach.
"Showing that something kills tumor cells is the beginning of the work, not the end of it," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "What we are presenting in Japan is a highly practical result: these cells appear active against the MGMT-positive fraction, which is the fraction temozolomide leaves behind. If that holds up, it tells us where this therapy belongs in the treatment sequence and which patients it is matched to. These remain preclinical findings, and we are presenting them where they can be rigorously examined by the field."
(Press release, SL Science, SEP 24, 2026, View Source [SID1234671048])